ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP) - Top-Institutions - MDSpire

ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP)

  • By

  • Azza Ismail

  • Rosamaria Nitti

  • Basil Sharrack

  • Manuela Badoglio

  • Pascale Ambron

  • Myriam Labopin

  • Tobias Alexander

  • John A. Snowden

  • Raffaella Greco

  • August 14, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party
    European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party

    Paris, N/A

    Key Differentiators

    • Hematology
    • Immunology
    • Stem Cell Transplantation

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Neurology
    • Stem Cell Transplantation

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Immunology
    • Neurology

  • #4

    University College London Hospitals (UCLH)
    University College London Hospitals (UCLH)

    London, N/A

    Key Differentiators

    • Hematology
    • Rheumatology
    • Stem Cell Transplantation

  • #5

    Northwestern University Feinberg School of Medicine
    Northwestern University Feinberg School of Medicine

    Chicago, IL

    Key Differentiators

    • Hematology
    • Immunology
    • Stem Cell Transplantation

Original Source(s)

ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP)

  • by Azza Ismail, Rosamaria Nitti, Basil Sharrack, Manuela Badoglio, Pascale Ambron, Myriam Labopin, Tobias Alexander, John A. Snowden, Raffaella Greco

  • August 14, 2024

Related Content

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations